Sweden’s BioArctic today revealed that the US Federal Trade Commission (FTC) has cleared the proposed deal with Bristol Myers ...

BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlu-Aß antibody programme effective after antitrust clearance and closing: Stockholm, Sweden Saturday, Fe ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement ...

Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as ...

STOCKHOLM, Feb. 18, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement ...

Novo Nordisk A/S was the biggest leader among large stocks during the session, gaining 5.8%, and DNO ASA gained 5.4%. Carlsberg A/S Series A rounded out the top three leaders on Friday, with shares ...

VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj., was approved on December 12, 2024. (Active ...

The company did not comment on the implications of the SAG meeting, but Swedish biopharma company BioArctic – which has joint commercial rights to the drug in the Nordic region – stressed that ...

AbbVie, meanwhile, had an antibody called ABBV-0805 in development with BioArctic, which cleared phase 1, but was side-lined for strategic reasons, and also abandoned an alpha-syn gene therapy ...